To validate whether ARID4B and MBD3 truly represent novel molecular vulnerabilities in KMT2A-r ALL, we used a GFP-based competition assay, recently described as a powerful screening methodology to identify novel therapeutic targets [43,44]. The gene discussed is ARID4B; the disease is acute lymphoblastic leukemia.